“The TRIUMPH-3 results show retatrutide prevents cardiovascular events.”

Not established

The reviewed evidence does not establish this statement. This does not prove it can never be true.

TRIUMPH-3 was not a definitive cardiovascular-outcomes trial. The sponsor reported a hazard ratio of 0.82 (95% CI 0.55 to 1.22) for the five-component major adverse cardiovascular event measure and 1.12 (95% CI 0.64 to 1.96) for the three-component measure. Both intervals include 1.0 and are wide, so studying a molecule in people with cardiovascular disease is not the same as showing it prevents events.

What this answer is based on

This answer uses a trial result reported by the study sponsor. A full report checked by other experts may not be available yet.

Limits of this answer

The TRIUMPH-3 cardiovascular-event analyses as disclosed by Lilly in July 2026, pending a full report. These limits show which substance, product, people, use, place, and time the answer covers. A different product or situation can have a different answer.

Topic

What a study measured about people's health, symptoms, or ability to function.